Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COCP
COCP logo

COCP Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cocrystal Pharma Inc (COCP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.980
1 Day change
-1.11%
52 Week Range
2.670
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

COCP is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading weakly under bearish technical conditions, has no supportive catalyst from news, no bullish proprietary signal, and no evidence of improving fundamentals or sentiment. Based on the current data, the clearer decision is to avoid buying and wait for a stronger setup.

Technical Analysis

Technically, COCP is in a bearish setup. The MACD histogram is negative and still contracting, RSI_6 at 35.291 is weak-neutral rather than bullish, and the moving average structure is bearish with SMA_200 > SMA_20 > SMA_5. Current price at 1.02 is below the pivot of 1.046 and only slightly above support at 0.97, which leaves limited upside confirmation and some downside risk toward support. The short-term stock trend data also points to weakness, with expected negative performance over the next week and month.

Positive Catalysts

  • No news in the recent week. No recent positive insider activity. No recent hedge fund accumulation. No AI Stock Picker signal. No SwingMax signal.

Neutral/Negative Catalysts

  • Bearish technical trend, no recent news catalysts, no significant hedge fund or insider buying, no recent congress trading data, and weak modeled near-term stock performance. The stock also lacks valuation support and has no clear fundamental momentum from the available data.

Financial Performance

No usable financial snapshot was provided because the data returned an error. As a result, there is no latest-quarter season or growth trend available to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of improving Wall Street sentiment. Overall, the available Wall Street view appears neutral to weak given the absence of positive revisions, targets, or supportive commentary.

Wall Street analysts forecast COCP stock price to rise
1 Analyst Rating
Wall Street analysts forecast COCP stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.995
sliders
Low
10
Averages
10
High
10
Current: 0.995
sliders
Low
10
Averages
10
High
10
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$7 -> $6
AI Analysis
2025-06-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$7 -> $6
AI Analysis
2025-06-21
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Cocrystal Pharma to $6 from $7 and keeps a Buy rating on the shares. The firm says CDI-988 demonstrated "further promise" via activity against emergent norovirus variants. It cites anticipated equity dilution for the target cut.

People Also Watch